

Tuolumne County
Emergency Medical Services Agency

Title: **Administration of Olanzapine**

Medical Director Signature: on file

EMS Coordinator Signature: on file

EMS Policy No. **552.95**

Creation Date: 11/16/2022

Revision Date:

Review Date: 2026

I) Purpose

To authorize paramedics to administer Olanzapine (Zyprexa) for patients with behavioral health emergencies.

II) Authority

Division 2.5, California Health and Safety Code, Section 1797.220, California Code of Regulations, Title 22, Division 9, Section 100144, 100145, 100146 and 100063.

III) Policy

A) Medication Information

1) Indications

(a) Olanzapine is indicated for the cooperative, anxious adult patient with primary behavioral health presentation and history of psychiatric disorder. These patients will commonly be hearing voices or having paranoid thoughts, often after noncompliance with taking their usual psychiatric medications.

2) Contraindications

- (a) Known allergy
- (b) Age less than 18 or over 65
- (c) Clinical intoxication with other substances
- (d) Agitation requiring restraints
- (e) Pregnancy
- (f) Not indicated for dementia related psychosis

3) Action

- (a) Primarily on dopamine and serotonin receptors
- (b) Works on dopamine D2 receptors in the mesolimbic pathway as an antagonist, blocking dopamine from potential action at the post-synaptic receptor
- (c) Onset: 10-15 minutes
- (d) Half Life: 21-54 hours

4) Adverse Effects

- (a) Dystonic reaction
- (b) Anticholinergic effects
- (c) CNS depression

5) Dosages and Routes

(a) 10mg Oral Disintegrating Tablet (ODT), should be handed to the patient for sublingual self-administration. No water is needed for the oral disintegrating tablet.

B) Training

1) Topics to be covered

- (a) Indications
- (b) Contraindications
- (c) Actions

- (d) Adverse Effects
- 2) Total time related to the above topics, including lecture, skills demonstration and practice, written and skills exam shall be no less than one (1) hour.
- 3) Course objectives specific to additional scope items. At the end of the training participants will be able to:
 - (a) Identify actions, indications, contraindications, adverse effects, administration guidelines, and precautions of olanzapine administration.
 - (i) Olanzapine should not be given in conjunction with Ondansetron.
 - (b) Demonstrate basic competency in administering olanzapine.
 - (c) Appropriately identify patients that meet olanzapine administration criteria.
- C) Continuous Quality Improvement (CQI)
 - 1) All olanzapine administrations will undergo review by provider agency and the TCEMSA CQI committee. Standard data elements shall be reported.
 - 2) Specific review for use of olanzapine will include
 - (a) Primary and Secondary Impression
 - (b) Patient Age
 - (c) Dose and time olanzapine administered
 - (d) Pre and post olanzapine vital signs and mental status
 - (e) Narrative detail supporting olanzapine administration
 - (f) Patient disposition